The global Interventional Cardiology Devices Market is
anticipated to reach around USD 25.2 billion by 2020. High incidence of heart
related disorders can directly impact product demand over the forecast period
(2012 to 2020). Valvuloplasty, angioplasty, and coronary thrombectomy are
procedures that need such devices. Key industry drivers are popularity of
minimally invasive surgeries and unhealthy lifestyles that trigger the onset of
cardiovascular anomalies. Also, rising cases of congenital heart diseases may
positively impact the overall market in the years to come. The use of novel
devices and new drug therapies in treating cardiovascular disorders has led to
higher life expectancy and better quality of life of patients. According to the
World Health Organization (WHO), number of deaths caused by cardiovascular
disorders is expected to be nearly 23.3 million by 2030.
The worldwide Interventional Cardiology Devices Market is
segmented on the basis of products and regions. On the basis of products, the
divisions are balloon inflation devices, PTCA balloons, stents, PTCA
guidewires, and interventional cardiology catheters. With a market share
exceeding 70%, interventional cardiology catheters dominated the global
industry in 2013.
Get Sample Copy of Report @ https://www.hexaresearch.com/research-report/interventional-cardiology-devices-industry
Application of
novel technologies that lower the risks of post-operative complications and
restenosis in angioplasty is a key factor that drives this segment. Different
types of stents are bio-absorbable, drug eluting, and metal. Bare metal stents
have helped in lowering the rates of restenosis by around 20 to 25 percent.
However, owing to greater effectiveness, bio-absorbable
& drug eluting stents are increasingly being used in place of bare metal
stents. The bio-absorbable stents segment may register the highest growth rate
in the forecast period. This is attributed to increasing awareness about the
benefits of such stents, such as their ability to lower the possibility of
restenosis. Catheters are a rapidly growing product segment because these are
utilized extensively in minimally invasive medical procedures. Due to the high
incidence of cardiovascular disorders, demand for angioplasty catheters may
surge in the forthcoming years. This segment is propelled by technological
advancements, widespread patient awareness, and prevalence of structural &
congenital heart ailments.
Geographically, the global interventional cardiology
devices market is categorized into Europe, North America, Asia Pacific, and
Rest of the World. With shares surpassing 35%, North America dominated the
overall industry in 2013. Widespread awareness in advanced economies and the
presence of large pediatric & geriatric populations are key regional
drivers. According to the American Heart Association, nearly 22% of the
pediatric population belonging to the 6 to 17 years age group suffers from
cardiovascular disorders. This owes to the prevalence of obesity in the region.
Asia Pacific can expand at the highest CAGR over the forecast period because of
popularity of minimally invasive procedures that ensure quick recoveries and
cause minimal trauma to patients.
Key companies in the worldwide interventional cardiology
devices industry are Boston Scientific, Abbott Laboratories, Terumo Medical
Corporation, B. Braun Melsungen AG, and Cordis Corporation among others. In
December 2016, Boston Scientific launched the SYNERGY stent. This product has
been approved by the US FDA for use in the treatment of coronary artery
disease. It is the first ever stent that offers synchronized polymer & drug
absorption. It enables complete & rapid arterial healing and thus lowers the
risks of complications pertaining to long term polymer exposure.
Browse Details of Report @ https://www.hexaresearch.com/research-report/interventional-cardiology-devices-industry
No comments:
Post a Comment